

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Shamir Eyal</u> (Last) (First) (Middle) <u>7 HA'ESHEL ST., PO BOX 3163</u> (Street) <u>CAESAREA L3 3079504</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/18/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>IceCure Medical Ltd. [ICCM]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Executive Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Ordinary shares</u>	<u>791,381⁽¹⁾</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Share option (right to buy)</u>	<u>(2)</u>	<u>01/23/2027</u>	<u>Ordinary shares</u>	<u>117,551</u>	<u>0.82⁽³⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(4)</u>	<u>05/02/2028</u>	<u>Ordinary shares</u>	<u>7,091</u>	<u>0.97⁽⁵⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(6)</u>	<u>08/14/2028</u>	<u>Ordinary shares</u>	<u>125,000</u>	<u>2.09⁽⁷⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(8)</u>	<u>03/28/2029</u>	<u>Ordinary shares</u>	<u>9,726</u>	<u>2.27⁽⁹⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(10)</u>	<u>05/21/2029</u>	<u>Ordinary shares</u>	<u>26,000</u>	<u>1.79⁽¹¹⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(12)</u>	<u>08/30/2030</u>	<u>Ordinary shares</u>	<u>27,332</u>	<u>1.56⁽¹³⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(14)</u>	<u>10/28/2030</u>	<u>Ordinary shares</u>	<u>32,500</u>	<u>1.68⁽¹⁵⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(16)</u>	<u>04/28/2031</u>	<u>Ordinary shares</u>	<u>4,319</u>	<u>5.78⁽¹⁷⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(18)</u>	<u>01/12/2032</u>	<u>Ordinary shares</u>	<u>143,324</u>	<u>3.64⁽¹⁹⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(20)</u>	<u>03/23/2032</u>	<u>Ordinary shares</u>	<u>13,720</u>	<u>2.84⁽²¹⁾</u>	<u>D</u>	
<u>Share option (right to buy)</u>	<u>(22)</u>	<u>02/19/2033</u>	<u>Ordinary shares</u>	<u>72,321</u>	<u>1.51⁽²³⁾</u>	<u>D</u>	

Explanation of Responses:

1. Represents (i) 77,894 ordinary shares, (ii) 525,949 restricted share units ("RSUs") granted on May 15, 2025, 25% of which vest on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 197,230 RSUs have vested and 328,719 remain unvested as of March 18, 2026, (iii) 121,893 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 65,645 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.

2. A total of 156,734 options were granted on January 23, 2017, and vested in equal quarterly installments of 6.25% beginning September 1, 2016. As of March 18, 2026, 117,551 options are fully vested and 39,183 have been exercised into ordinary shares.

3. The options were granted with an exercise price of NIS 2.54 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$0.82 per share.

4. The options were granted on May 2, 2018, and vested in equal quarterly installments of 6.25% beginning May 2, 2018. As of March 18, 2026, all 7,091 options are fully vested.

5. The options were granted with an exercise price of NIS 2.992 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$0.97 per share.

6. The options were on August 14, 2018, and vested in equal quarterly installments of 6.25% beginning August 14, 2018. As of March 18, 2026, all 125,000 options are fully vested.

7. The options were granted with an exercise price of NIS 6.472 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$2.09 per share.

8. The options were granted on March 28, 2019, and vested in equal quarterly installments of 6.25% beginning March 28, 2019. As of March 18, 2026, all 9,726 options are fully vested.

9. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$2.27 per share.

10. The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning May 21, 2019. As of March 18, 2026, all 26,000 options are fully vested.

11. The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$1.79 per share.

12. The options were granted on August 30, 2020, and vested in equal quarterly installments of 6.25% beginning August 30, 2020. As of March 18, 2026, all 27,332 options are fully vested.

13. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$1.51 per share.

14. The options were granted on October 28, 2020, 25% of which vested on October 28, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 32,500 options are fully vested.

15. The options were granted with an exercise price of NIS 5.2128 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$1.68 per share.

16. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 4,319 options are fully vested.

17. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$5.78 per share.

18. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 143,324 options are fully vested.

19. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$3.64 per share.

20. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 12,862 options are vested.

21. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$2.84 per share.

22. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 54,240 options are vested.

23. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD \$1.00 as of March 11, 2026, resulting in an exercise price of \$1.51 per share.

/s/ Eyal Shamir

03/25/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.